The Indian Council of Medical Research (ICMR) has licensed homegrown medical technologies to Indian pharmaceutical companies, marking a significant step in indigenous healthcare innovation.These technologies include a potential treatment for cervical pre-cancer (CIN) and vaccines against typhoid and gut infections.The transfer under the Patent Mitra Initiative aims to boost affordable healthcare access and reduce reliance on imported tech.SHetA2, a treatment for CIN caused by HPV, could offer a safer alternative to surgery.Two vaccines developed by NIRBI, Kolkata, are being licensed to Biological E for typhoid and multi-disease protection.Dr.Rajiv Bahl emphasized partnerships between researchers and industry to strengthen India's biomedical ecosystem.

This move aligns with ICMR's efforts to support indigenous innovation through patent protection and regulatory facilitation, ensuring affordable medicines reach patients.